COVID-19

More than three-quarters of deaths averted were attributed to the direct protection against severe symptoms provided by vaccination, leading to lower mortality rates.

Infection in pregnancy increases the risk for preterm delivery and other adverse pregnancy outcomes, including stillbirth.

At 1 month, a 50-µg booster dose of mRNA-1273.214 had a potent neutralizing antibody response against the Omicron variants in all individuals, regardless of prior infection.

The Sanofi-GSK vaccine demonstrated a favorable safety and tolerability profile throughout stage 1 and stage 2 of the VAT08 trial, according to the researchers.

Pharmacy and public health have a long history of collaboration during an emergency.

Kai Zhao, PhD, director of the Nasal Physiology and Therapeutic Center in the Department of Otolaryngology at Ohio State University College of Medicine, discusses his research investigating the persistence of taste and smell loss among patients who have been infected and reinfected with COVID-19.

Analysis shows that individuals who received treatment within 3 days of symptom onset with tixagevimab and cilgavimab reduced their risk by 88% compared with the placebo.

Study results showed that a lower proportion of participants treated with LAGEVRIO had an acute care visit compared with those who received the placebo.

Data show significantly higher geometric mean titer ratios, meeting prespecified endpoints for superiority against the variant.

Kai Zhao, PhD, director of the Nasal Physiology and Therapeutic Center in the Department of Otolaryngology at Ohio State University College of Medicine, discusses how patients who have experienced a loss of taste and smell following COVID-19 infection may be impacted by this symptom for years without realizing it.

Now we must turn our focus to all recommended vaccinations.

Hispanic and individuals with lower incomes experienced sharper drops, reflecting emerging barriers and exacerbation of long-standing hurdles, analysis results indicate.

Since the COVID-19 pandemic began, more than 10.6 million children have tested positive for the virus in the United States.

Paxlovid treats COVID-19 in adults who do not require supplemental oxygen and who are at an increased risk of progression to severe disease.

Although the COVID-19 pandemic saw the rapid hemorrhaging of women from careers in science and medicine, research shows the toxicity experienced by women may be structural in nature.

Data from the phase 2/3 TeenCOVE trial in adolescents met the primary immunogenicity endpoint.

COVID-19 vaccine recommendations have parallel tracks for adults and parallel tracks for children broken down into whether an individual is immunocompromised.

Baricitinib (Olumiant) is indicated for the treatment of rheumatoid arthritis and COVID-19 in hospitalized adults.

The FDA Vaccines and Related Biological Products Advisory Committee voted nearly unanimously for an emergency use authorization for the Novavax COVID-19 vaccine, NVX-CoV2373, for use in individuals 18 years of age and older.

Pharmacies can help bring inequities plaguing health care systems to an end to ensure the COVID-19 pandemic does not follow trends of inequity experienced in the HIV pandemic.

The application submission paves the way for a potential decision as early as this month.

Research suggests that individuals receiving a vaccine, such as ones from AstraZeneca and Johnson & Johnson, were more vulnerable to infection by new variants.

Using machine learning, they find patterns in electronic health record data to help ascertain which individuals likely have the condition.

Consequences for untreated STEMI patients following the COVID-19 pandemic could include increased mortality, heart failure, and morbidities.